• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ThermoGenesis, TotipotentRx merge to form Cesca

ThermoGenesis, TotipotentRx merge to form Cesca

July 17, 2013
CenterWatch Staff

ThermoGenesis, a supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, and TotipotentRx, a privately held  developer of  cell-based therapies in  regenerative medicine, have entered into a definitive merger agreement to form a new company called Cesca Therapeutics.

The combined company is expected to become a fully-integrated regenerative medicine company, developing clinically validated, commercially scalable point-of-care cell therapies for major therapeutic markets including orthopedic, cardiovascular and neurologic indications.

ThermoGenesis will issue approximately 12,491,000 shares of its common stock to TotipotentRx, which equals approximately $18.6 million, based on ThermoGenesis' closing stock price on July 15. The agreement has been unanimously approved by the boards of directors of both companies. The transaction is expected to close in the fourth quarter.

"Our products will give healthcare providers the ability to consistently execute every step of the cell therapy treatment process, at the patient's bedside, in less than an hour and at a fraction of the cost of typical cell therapy models,” said Matthew T. Plavan, chief executive officer of ThermoGenesis, explaining that the merger will allow it to commercialize these new cell therapies by leveraging TotipotentRx’s CRO division and a cell therapy partnership with Fortis Healthcare System.

TotiRx is a regenerative medicine development company that has eight autologous cell therapies in various stages of clinical development targeting areas of high unmet medical need, including osteoarthritis, avascular necrosis, acute myocardial infarction and critical limb ischemia.

Plavan will be chief executive officer of the new company and Kenneth L. Harris, chairman and chief executive officer of TotipotentRx, will be president and join the board of directors.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing